Method for detecting c. albicans

ABSTRACT

A HWP1 gene sequence or fragment or variants thereof as a target region in a nucleic acid based assay for  Candida albicans  and an isolated nucleic acid molecule useful as a probe for identifying  C. albicans  in a sample. A method for the detection of  C. albicans  in a sample and quantification of HWP1 gene expression in  C. albicans  is also described.

The invention relates to a novel nucleic acid based gene target sequence useful in the detection of Candida albicans.

INTRODUCTION

Fungal infections have become more prevalent in recent years due to extensive use of antifungal drugs and the emergence of resistant strains. These infections are an important cause of morbidity and mortality in immunocompromised and immunocompetent hosts. Candida spp. most notably Candida albicans are the most common organisms associated with fungal disease. Recent data from the US National Noscomial Infections Surveillance system rank C. albicans as the fourth most common cause of bloodstream infections. C. albicans causes superficial and systemic disease and even with antifungal therapy, mortality of patients with invasive candidiasis can be up to 40% (1). Those most susceptible to infection include immunocompromised patients including cancer patients, organ transplant recipients and HIV positive individuals.

Standard methods for the diagnosis of C. albicans include culture and histopathology but the sensitivity and specificity of these methods is limited. In many cases by the time a positive result is obtained the disease is well advanced. Identification of C. albicans in clinical samples using conventional methods of morphological and metabolic characteristics requires one to several days for detection after isolation. In an effort to overcome this slow detection time several methods have been developed including antibody detection (2), cell wall mannan (3) and specific antibody combined with a PCR-based method (4). More recently various PCR assays have been developed and combined with probe hybridisation techniques (5, 6). While these assays offer several advantages over conventional methods some problems still exist, for example extended incubation times and cumbersome washing steps, which limit their use in a clinical situation. Real-time PCR assays have been developed using as targets the 18S rDNA gene or the internal transcribed spacer region (ITS2) (7, 8, 9, 10).

Any rapid diagnostic test for early detection of fungal infection has important therapeutic potential.

STATEMENTS OF INVENTION

According to the invention there is provided a HWP1 gene sequence or fragment thereof as a target region in a nucleic acid based assay for Candida albicans. In one embodiment of the invention the HWP1 gene sequence comprises a nucleic acid sequence of SEQ ID No. 1 or fragment or variants thereof.

The invention also provides a primer derived from HWP1 gene a comprising nucleic acid SEQ ID No. 2 or its reverse compliment or derivative, variants or mutants thereof.

The invention also provides a primer derived from HWP1 gene comprising nucleic acid SEQ ID No. 3 or its reverse compliment or derivative, variants or mutants thereof.

The invention further provides a probe derived from HWP1 gene comprising nucleic acid SEQ ID No. 4 or its reverse compliment or derivative, variants or mutants thereof.

The invention also provides a primer derived from HWP1 gene comprising nucleic acid SEQ ID No. 12 or its reverse compliment or derivative, variants or mutants thereof.

The invention also provides a primer derived from HWP1 gene comprising nucleic acid SEQ ID No. 13 or its reverse compliment or derivative, variants or mutants thereof.

The invention further provides a probe derived from HWP1 gene comprising nucleic acid SEQ ID No. 14 or its reverse compliment or derivative, variants or mutants thereof.

The invention further provides a probe derived from HWP1 gene comprising nucleic acid SEQ ID No. 15 or its reverse compliment or derivative, variants or mutants thereof.

The invention also provides a primer/probe combination comprising nucleic SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14 and SEQ ID No. 15 or reverse compliment or derivative, variants or mutants thereof.

The invention also provides a nucleic acid comprising a nucleic acid sequence selected from any one or more SEQ ID No. 1 to 4 and 12 to 15 or derivative, variants or mutants thereof.

One aspect of the invention provides an isolated nucleic acid molecule useful as a probe for identifying C. albicans in a sample selected from any one or more of

-   -   (i) nucleotide sequence of SEQ ID No. 1 to 4 and 12 to 15;     -   (ii) the nucleotide sequence complementary to (i);     -   (iii) a portion of the nucleotide sequence (i) of sufficient         length to determine the presence of C. albicans in a sample; and     -   (iv) the nucleotide sequence complementary to (iii)

Another aspect of the invention provides a method for the detection of C. albicans comprising the steps of;—

-   -   isolating a sample;     -   extracting or releasing DNA from the sample;     -   amplifying a target sequence using an in vitro amplification         technology; and     -   determining the presence or absence of C. albicans in the sample         using nucleic acid probes, peptide nucleic acid (PNA) probes,         other hybrid molecules or antibodies to the target amplified         nucleic acid to detect the amplified target.

The invention also provides a method for the quantification of HWP1 gene expression in C. albicans comprising the steps of;—

-   -   isolating a sample;     -   extracting or releasing RNA from the sample;     -   carrying out reverse transcription to produce cDNA;     -   amplifying a target sequence using an in vitro amplification         technology; and     -   quantifying the HWP1 gene expression in the sample using nucleic         acid probes, peptide nucleic acid (PNA) probes, other hybrid         molecules or antibodies to the target amplified nucleic acid to         detect the amplified target.

The invention further provides a method for the detection of C. albicans comprising the steps of isolating a sample, extracting or releasing the nucleic acid and directly detecting the nucleic acid using a specific nucleic acid probe, peptide nucleic acid (PNA) probes, other hybrid molecules or antibodies to the target amplified nucleic acid.

In one embodiment of the invention the target sequence is a HWP1 gene sequence or derivative or variants or mutants thereof. Preferably the target sequence comprises nucleic acid SEQ ID No. 1 or derivative or variants or mutants thereof.

In one embodiment of the invention the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14 and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.

Preferably the target sequence is detected using fluorescence resonance energy transfer (FRET).

The invention also provides a method for determining the efficacy of an anti-fungal agent comprising the steps of;—

-   -   quantifying the expression of the HWP1 gene or derivative or         mutants or variants thereof prior to administration of therapy.     -   administering an anti-fungal agent; and     -   quantifying the expression of the HWP1 gene after anti-fungal         therapy.

In another embodiment of the invention the expression of the HWP1 gene is monitored following administration of a combination of anti-fungal therapies.

In a further embodiment of the invention the expression of the HWP1 gene is monitored following administration of an immune-modulator drug.

In a further embodiment of the invention the expression of the HWP1 gene is monitored following administration of an immune-stimulator drug.

In a further embodiment of the invention the expression of the HWP1 gene is monitored following administration of a combination of an anti-fungal therapy along with an immune-modulator or immune-stimulator drug.

In one embodiment of the invention the expression levels of the HWP1 gene is monitored over a period of time.

In one embodiment of the invention the clinical sample is selected from any one or more of blood, sputum, urine, BAL, saliva, stool sample, vaginal and mouth swab periodontal tissue, or bone, environmental sample, manufacturing process sample, sterile injectable products for release (e.g. injectable drugs undergoing product release in pharma or biotech industry).

The invention further provides a method of screening anti-fungal compounds for the treatment and/or prophylaxis of C. albicans fungal infection, comprising detecting the presence or absence of C. albicans before and after treatment with the anti-fungal compounds using the HWP1 gene or derivative, mutants or variants thereof.

The invention further provides a method of screening anti-fungal compounds for the treatment and/or prophylaxis of C. albicans fungal infection in combination with immune-modulator or immune-stimulator drugs, comprising detecting the presence or absence of C. albicans before and after treatment with the anti-fungal and immune-modulator compounds using the HWP1 gene or derivative, mutants or variants thereof.

The invention further provides a method of screening a combination of anti-fungal compounds for the treatment and/or prophylaxis of C. albicans fungal infection, comprising detecting the presence or absence of C. albicans before and after treatment with a combination of the anti-fungal compounds using the HWP1 gene or derivative, mutants or variants thereof.

The invention also provides a diagnostic kit comprising a HWP1 gene sequence for detecting the presence of C. albicans in a sample. In one embodiment the HWP1 gene sequence comprises SEQ ID No. 1 or derivative, mutants or variants thereof.

In another embodiment of the invention the diagnostic kit comprises a nucleic acid sequence selected from any one or more of SEQ ID No. 2 to 4 and 12 to 15 for detecting the presence of C. albicans in a sample.

Preferably the sample is selected from any one or more of a clinical, veterinary, environmental, industrial, production process or food sample. The sample may be in the form of blood, sputum, urine, bronchoalveolar lavage (BAL), saliva, stool sample, vaginal and mouth swab or bone or of an environmental or industrial or production process swab sample.

The invention also provides use of a nucleic acid sequence selected from any one or more of SEQ ID No. 1 to 4 and 12 to 15 or a derivative, mutants or variants thereof in the detection of C. albicans.

The invention also provides use of the HWP1 gene, HWP1 RNA or a derivative, mutants or variants thereof for use in the detection of C. albicans. Preferably the HWP1 gene comprises the forward DNA strand and the nucleotide sequence complementary thereto.

The invention further provides use of a probe and/or primer or probe/primer combination or reverse compliment thereof as hereinbefore described in the detection of C. albicans.

BRIEF DESCRIPTION OF THE INVENTION

The invention will be more clearly understood from the following description thereof with reference to the accompanying drawings in which:—

FIG. 1 shows the alignment of the full sequence of the Candida albicans hyphal wall protein 1 (HWP1) gene, Accession No. U64206 and a partial sequence of the Candida albicans hyphal wall protein 1 (HWP1) Accession No. U29369 both sequences available in GenBank database www.ncbi.nlm.nih.gov/Genbank/index.html). The position of the primers and probes of SEQ ID No. 2 to and 12 to 15 are indicated;

FIG. 2 is a partial HWP1 sequence generated for six strains of Candida albicans. The location of primers HWP15 and HWP6-LC640 (italics) which is labelled and used in combination with a labelled probe HWP1a-flu (underlined) are indicated;

FIG. 3 is a graph showing LightCycler melt curve data generated for Candida albicans clinical isolates using HWP1 specific labelled primer-probe combination. A single melt peak at approx 57° C. was generated for all isolates tested;

FIG. 4 is a graph showing LightCycler melt curve data generated for Candida albicans reference strains using HWP1 specific labelled primer-probe combination. A single melt peak at approx 57° C. was generated for all isolates tested;

FIG. 5 is a graph showing the sensitivity data for the HWP1 assay generated using specific labelled primer-probe combination. The quantification data shown represents detection of 10⁵ to 1 copy of the HWP1 gene target;

FIG. 6 is a graph showing the sensitivity data for the HWP1 assay generated using serial dilutions of C. albicans cells;

FIG. 7 is a graph showing the detection limit of the assay for the detection of C. albicans in blood;

FIG. 8 is a graph showing the specificity of the RNA-based assay for C. albicans isolates;

FIG. 9 is a graph showing the specificity of the RNA-based assay for C. albicans isolates;

FIG. 10 is a graph showing the specificity of the HWP1 target for C. albicans;

FIG. 11 shows quantification data representing detection of 104 to 1 copy of the HWP1 gene target using the RNA-based assay;

FIG. 12 shows quantification curves of the cDNA used in the real time PCR RNA based assay; and

FIG. 13 shows the standard curve generated from the dilutions obtained in FIG. 12;

DETAILED DESCRIPTION

We have identified a gene target (HWP1) sequence suitable for the development of a rapid molecular diagnostic test for C. albicans.

The HVP1 (hyphal wall protein 1) gene was first described by Staab and Sundstrom (11) as a developmentally expressed gene in C. albicans. They went on further to describe the gene as encoding an outer mannoprotein Hwp1 with a cell surface exposed NH₂-terminal domain and COOH-terminal features conferring covalent integration into cell wall B-glucan. In 1998 the same authors (12) further described the role of the Hwp1 protein (13). The gene was subsequently identified as functioning downstream of EFG1, TUP1 and RBF1 regulators in the morphological development of C. albicans (14).

We have identified a HWP1 gene sequence which is specific for C. albicans. The gene would therefore be a useful diagnostic target for the development of a nucleic acid based diagnostic test for the detection of the fungal pathogen C. albicans. The key advantage of this target sequence is its specificity for C. albicans. This is significant since over 50% of fungal infections are caused by C. albicans (14).

Novel oligonucleotide primers and probes were designed from the HWP1 gene of Candida albicans for the amplification, identification and detection of the organism.

The target provides a new gene target sequence for this important clinical pathogen. The identification of a C. albicans specific gene target also provides the potential for further innovative assay development.

The HWP1 gene (SEQ ID No. 1) was used as a target for development of a real-time PCR assay for C. albicans on the LightCycler. The assay was found to be 100% specific for C. albicans with no cross reaction with any other non-albicans Candida species or other commonly occurring clinical pathogens. Systems employing an amplification technology such as the Polymerase Chain Reaction (PCR), Nucleic Acid Sequence Based Amplification (NASBA), Transcription Mediated Amplification (TMA) are obviously more sensitive than methods not using an amplification step. The examples of the invention described here employ the PCR process, using PCR primers followed by detection using hybridisation probes. Nucleic acid based technologies fall into two categories. The first employs molecular methods to detect target sequences directly in samples or sub-cultured microbial isolates. The second category involves nucleic acid amplification technologies to amplify the target sequence prior to detection. Which method is employed depends on several factors including, labour costs, the need for rapid results and the endpoint application. While the examples use the latter strategy in the development of a diagnostic assay for C. albicans the nucleic acid target sequence in this invention could be advantageously used in either category and it will be understood that all nucleic acid based technologies are covered within the scope of the invention.

From sequence information generated, PCR primers were designed for amplification of the C. albicans HWP1 target sequence. Detection of the amplified target was achieved using a combination of a primer labelled with LC640 and a probe labelled with fluorescein by the process of fluorescence resonance energy transfer (FRET).

The specificity of a primer and probe combination was verified using DNA extracted from a panel of geographically distinct C. albicans reference strains and clinical isolates as well as from other Candida and non-Candida fungal species. The specificity was further cross checked against DNA extracted from a panel of bacterial species and human DNA. The assay has been shown to be specific for the HWP1 gene sequence of the C. albicans isolates tested (FIGS. 3 & 4). The detection limit of the assay was established (using serially diluted DNA from the type strain of C. albicans) and can reliably detect between 1 and 10 copies of the gene (FIG. 5). Therefore the HWP1 gene is not only a specific target sequence it also represents a sensitive target suitable for detection at low copy number.

The major problem facing clinicians today is that currently available microbial diagnostics are too slow to provide clinically useful information. This information is required firstly to administer appropriate therapy and secondly to monitor the administered drug efficacy. The advances being made in molecular diagnostics promise results which will be available fast enough to revolutionise the practice of medicine. Novel diagnostic approaches will ensure better management of patients, should reduce health costs and impact on the spread of antibiotic resistance.

Early detection of C. albicans in samples using rapid diagnostic tests such as real-time PCR, reduces the need for prophylactic antifungal agents and leads to timely diagnosis and appropriate treatment of the infection.

Using the gene target described a rapid diagnostic test is possible for detecting C. albicans in a sample. This provides the potential for an early guide to appropriate intervention.

The gene target shows no cross reaction with other Candida species and the real-time PCR has the potential to detect one copy number of the target gene, thus providing a very sensitive assay. In addition the RNA transcribed from the gene target may distinguish between viable and non-viable organisms.

The potential also exists to use gene target for development of RNA-based quantitative reverse transcriptase real-time PCR assays for C. albicans. Such assays would determine expression of the gene and have the potential to be used as a theranostic marker monitoring the response to antifungal therapy, to a combination of antifungal therapies, to immune-modulating therapies or to a combination of both antifungal therapies and immune modulating. A reduction in expression of the gene would indicate a satisfactory response to therapy.

The invention will be more clearly understood from the following examples.

EXAMPLES C. albicans Real Time PCR Assay Using the Specific Target HWP1

A real time PCR assay for C. albicans using the specific gene target HWP1 was developed for use on the LightCycler™. The assay uses a labelled primer-probe combination which operates by the process of fluorescence resonance energy transfer (FRET). The assay was developed as follows:

Partial HWP1 sequence for six Candida albicans strains was generated (FIG. 2) by amplifying the HWP1 gene using primers (HWP15 and HWP6) designed from the HWP1 gene.

HWP15: 5′ aaa ggg aga gtt ttg gta ggc 3′ (SEQ ID No. 2) HWP6: 5′ tcg gta tta aag tcg caa ca 3′ (SEQ ID No. 3)

Thermocycling conditions included a 10 minute denaturation step at 95° C. followed by amplification at 50° C. for 15 seconds and extension at 72° C. for 10 seconds for 45 cycles. All PCR products generated were sequenced. Prior to sequencing, products were treated to remove single stranded DNA and free nucleotides using the PCR product pre-sequencing kit (USB).

2. From the sequence information generated a labelled primer-probe FRET pair (HWP6-LC640 & HWP1 a-flu) was designed as follows.

HWP6-LC640: 5′ tcg gta tta aag tcg caa ca 3′ (SEQ ID No. 3) HWP1a-flu: 5′ tat gac tac att ttg ttt cac tt 3′ (SEQ ID No. 4)

The primer-probe FRET pair was used in combination with the HWP15 forward primer on the LightCycler™. This combination works by fluorescence resonance energy transfer (FRET) from the labelled probe to the labelled primer. FRET occurs as the donor fluorophore (fluorescein on the HWP1a probe) is excited photometrically and transfers its energy to the acceptor fluorophore (LC-640 on HWP6). The acceptor fluorophore emits light at a longer wavelength and is detected by the instrument. This labelled primer-probe combination is less frequently used than the conventional dual labelled probe set-up, but works in exactly the same way with the exception that the labelled primer is involved in the amplification of the product. PCR amplification and detection was performed on the LightCycler™ real time PCR machine (Roche). LightCycler Faststart DNA Master Hybridization Probes kit (Roche) was used for amplification. A final concentration of 4 mM MgCl₂, 0.2 μM hybridisation probe, 0.5 μM primers were used in addition to 2 μL of template DNA. The thermocycling conditions included a 10 minute denaturation step at 95° C. followed by amplification at 50° C. for 15 seconds and extension at 72° C. for 10 seconds for 45 cycles. The melt curve profile was as follows: 95° C. for 60 sec, 45° C. for 60 sec and 80° C. for 0 sec. Fluorescence acquisition was continuous. One cycle of cooling to 40° C. was also included.

3. The specificity of a primer (HWP15/HWP6-LC640) and probe combination (HWP1a-flu) was verified using DNA extracted from a panel of geographically distinct C. albicans reference strains and clinical isolates (Table 1) as well as from other Candida species and non-Candida fungal species, bacterial species and human DNA.

TABLE 1 Country Strain No Source Strain ID Information of origin 562 (T) CBS* C. albicans Patient with Uruguay interdigital mycosis 3156 NCPF** C. albicans 1965 Serotype B UK 3345 NCPF C. albicans Arm abscess UK 3822 NCPF C. albicans Mouth isolate UK AIDS patient 3328 NCPF C. albicans Renal transplant UK patient 2700 CBS C. albicans Macroglossia Brazil mycotica 15572 IHEM*** C. albicans Blood, Candidemia Belgium 14543 IHEM C. albicans Blood, pulmonary Belgium stenosis 14583 HEM C. albicans Blood, ovarian Belgium cancer 4013 IHEM C. albicans Blood Belgium 4154 IHEM C. albicans Blood Belgium 6209 IHEM C. albicans Blood Belgium thrombobacytopenic purpura 9559 IHEM C. albicans Blood Iowa USA 16908 IHEM C. albicans Blood, Candidemia Belgium 16733 IHEM C. albicans Blood, Candidemia Belgium AIDS 6134 IHEM C. albicans Blood, Kidney Belgium cancer 6198 IHEM C. albicans Blood, acute Belgium lymphoblastic leukemia 4140 IHEM C. albicans Blood, pulmonary Belgium stenosis 15640 HEM C. albicans Blood TB Belgium 9561 HEM C. albicans Blood kidney Iowa USA cancer 16909 HEM C. albicans Blood candidemia Belgium 43 clinical UCHG**** C. albicans unknown Galway isolates *Centraalbureau voor Schimmelcultures **National Collection of Pathogenic Fungi ***Belgian Co-ordinated Collection of Microorganisms ****University College Hospital Galway

The fungal species tested included Candida dubliniensis, Candida tropicalis, Candida krusei, Candida glabrata, Candida parapsilosis, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Candida guillermondii.

The bacterial species tested included Enterobacter aerogenes, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Pantoea agglomerans, Acinetobacter baumannii, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus agalactiae, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus haemolyticus, Stenotrophomonas maltophilia.

Human genomic DNA was also tested.

Extraction of DNA from these panels of organisms was carried out using the MagNA Pure LC automated nucleic acid extraction system (Roche) using the MagNA Pure LC DNA isolation kit III (Roche) for bacteria and fungi according to manufacturers instructions. DNA was quantified spectrophotometrically at 260 nm. The assay has been shown to be specific for all of the C. albicans isolates tested (FIGS. 3 and 4). No melt peak was obtained for any of the other fungal or bacterial species tested indicating the specificity of the HWP1 target for C. albicans. In addition no melt peak was obtained for human DNA. This indicates that the primer/probe combination is specific for the HWP1 target sequence and is not cross reacting with other material in the samples such as non-specific DNA.

The detection limit of the assay was established (using serially diluted DNA from the type strain of C. albicans) and can reliably detect between 1 and 10 copies of the gene (FIG. 5). Therefore this is not only a specific target it also represents a sensitive target suitable for detection at low copy number.

The detection limit of the assay using dilutions of C. albicans cells was established. Serial dilutions were prepared from an overnight culture of the organism (10⁹ cells/ml) and DNA was extracted from each dilution using the MagNA Pure LC DNA isolation kit III (Roche) for bacteria and fungi according to the manufacturer's instructions. The DNA was used in the real-time PCR assay. The assay can reliably detect 10 cells when this method is used (FIG. 6).

The detection limit of the assay for detecting C. albicans in blood was also established. C. albicans cells were spiked into blood and DNA was extracted from each dilution using the MagNA Pure LC DNA isolation kit III (Roche) for bacteria and fungi according to the manufacture's instructions. This DNA was used in the real-time PCR assay. The assay can reliably detect 10 cells when this method is used (FIG. 7).

The HWP1 gene target also has the potential to be used for the development of an RNA-based assay for C. albicans. A reverse transcriptase real-time PCR assay for the organism may be used to quantify HWP1 gene expression providing a theranostic marker to monitor the efficacy of antifungal therapy. Reduced expression of the HWP1 gene would indicate that the infection is responding to therapy and appropriate steps could then be taken to modify treatment if required.

RNA-Based Assay for the HWP1 Gene.

In order to demonstrate the potential of the HWP1 target for use in an RNA-based assay, additional primers and probes were designed from the coding region of the gene (FIG. 1).

The additional primer and probe sequences are as follows:

HWPx: 5′ tgctcaacttattgctat 3′ (SEQ ID No 12) HWPy: 5′ ttgtcacaaggaacatc 3′ (SEQ ID No 13) HWPz-flu: 5′ aacagaggaagctcttattca 3′ (SEQ ID No 14) HPWw-LC: 5′ agagatcttatgattactatcaaga 3′ (SEQ ID No 15)

The specificity of this primer (HWPx/HWPy) and probe (HWPz-flu/HPWw-LC) combination was verified using DNA extracted from a panel of geographically distinct C. albicans reference strains and other Candida species (Table 2), bacterial species and human DNA. PCR amplification and detection was performed on the LightCycler™ real time PCR machine (Roche). LightCycler Faststart DNA Master Hybridization Probes kit (Roche) was used for amplification. A final concentration of 4 mM MgCl₂, 0.2 μM hybridisation probes, 0.5 μM primers were used in addition to 2 μL of template DNA. The thermocycling conditions included a 10 minute denaturation step at 95° C. followed by amplification at 50° C. for 15 seconds and extension at 72° C. for 10 seconds for 45 cycles. The melt curve profile was as follows: 95° C. for 60 sec, 45° C. for 60 sec and 80° C. for 0 sec. Fluorescence acquisition was continuous. One cycle of cooling to 40° C. was also included.

TABLE 2 Country Strain No Source Strain ID Information of Origin 3345 NCPF C. albicans Arm abscess UK 3156 NCPF C. albicans 1965 Serotype B UK 562 (T) CBS C. albicans Patient with Uruguay interdigital mycosis 3328 NCPF C. albicans Renal transplant UK patient 2700 CBS C. albicans Maroglossia Brazil mycotica 14583 IHEM C. albicans Blood ovarian Belgium cancer 9559 IHEM C. albicans Blood Iowa USA 4154 IHEM C. albicans Blood Belgium 9561 IHEM C. albicans Blood kidney Iowa USA cancer 15572 IHEM C. albicans Blood candidemia Belgium 6209 IHEM C. albicans Blood Belgium thrombobacytopenic purpura 6198 IHEM C. albicans Blood Belgium lymphoblastic leukaemia 16733 IHEM C. albicans Blood candidemia Belgium AIDS 16908 IHEM C. albicans Blood candidemia Belgium 15640 IHEM C. albicans Blood TB Belgium 4140 IHEM C. albicans Blood pulmonary Belgium stenosis 14543 IHEM C. albicans Blood pulmonary Belgium stenosis 4013 IHEM C. albicans Blood Belgium

The fungal species tested included Candida dubliniensis, Candida tropicalis, Candida krusei, Candida glabrata, Candida parapsilosis, Candida kefyr, Candida guillermondii.

The bacterial species tested included Enterobacter aerogenes, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Pantoea agglomerans, Acinetobacter baumannii, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermis, Staphylococcus haemolyticus, Stenotrophomonas maltophilia.

The assay has been shown to be specific for all of the C. albicans isolates tested (FIG. 9). No melt peak was obtained for any of the other fungal (FIG. 9) or bacterial species (FIG. 10) tested indicating the specificity of the HWP1 target for C. albicans. In addition, no melt peak was obtained for human DNA. This indicates that the primer/probe combination is specific for the HWP1 target sequence and is not cross reacting with other material in the samples such as non-specific DNA.

The detection limit of the assay was established (using serially diluted DNA from the type strain of C. albicans) and can reliably detect between 10 and 1 copy of the gene (FIG. 11). Therefore this assay is suitable for detection of low copy number and therefore low cell numbers of C. albicans in samples.

For the RNA-based assay, RNA was extracted from an overnight culture of C. albicans type strain 562 using the Ambion RiboPure Yeast kit (Ambion). RNA was treated with DNAfree (Ambion) to ensure the absence of genomic DNA contamination. Analysis of the RNA prior to use was carried out on the Agilent Bioanalyzer (Agilent UK). This confirmed the yield and purity of the RNA. cDNA synthesis was carried out on RNA verified to be free from genomic DNA. RNA was verified DNA free by using the RNA as template in the real-time PCR assay using the primers HWPx/y and probes HWPz-flu/LC probes as described previously. DNA free RNA was identified as that which did not give a signal in the assay. cDNA was generated by incubating the RNA at 80° C. with 0.05 μM of reverse primer (HWPy) for 3 minutes for denaturation followed by immediate cooling on ice. MMLV reverse transcriptase (100 U) (Ambion), 2 μl reaction buffer, 400 nM dU:dNTP were added to the mixture and incubated at 42° C. for 1 hour. The single stranded cDNA produced in this reaction was used as template in the real-time PCR assay. FIG. 12 shows the quantification curves obtained for dilutions of this cDNA used in the real-time PCR assay. FIG. 13 shows the standard curve generated from these dilutions. Such an assay has the potential to be used for monitoring the expression of the HWP1 gene providing a theranostic marker and allowing the distinction between live and dead cells.

The present invention also includes within its scope isolated nucleic acid and polypeptides derived from the HWP1 gene of C. albicans and hybrid PNA sequences that are useful reagents for diagnosis of fungal disease, components of anti-fungal vaccines and/or as targets for anti-fungal drugs and/or immune-modulating drugs. The method of the invention may be used for screening compounds for their ability to interfere with the C. albicans life cycle or to inhibit C. albicans infection such compounds including anti-fungal therapies, immune-modulating drugs and/or other drugs/therapies.

Another method for the detection of target sequences in a sample which may be used within the scope of the present invention include nonamplified direct nucleic acid based tests which utilise nucleic acid probes that are specific for a unique nucleic acid sequence present in the organism to be detected. The probes are usually labelled with fluorescent or chemiluminescent labels or other labels to facilitate detection and quantitation. The sample is treated to release nucleic acids from the target organism, if it is present. Following this, the labelled DNA probe specifically combines with the target sequence to form a stable probe-target sequence hybrid. The hybrid is separated or discriminated from nonhybridized target and probes, and the signal emitted by label in the hybrid is measured.

The invention is not limited to the embodiments herein before described which may be varied in detail.

REFERENCES

-   1. Chandra J., Kuhn D., Mukherjee P. K., Hoyer L. L., McCormick T. &     Ghannoum M. A. 2001. Biofilm formation by the fungal pathogen     Candida albicans: Development, Architecture, and Drug Resistance. J.     Bacteiiol. 183(18):5385-5394 -   2. Young R. and Bennet J. 1971. Invasive aspergillosis. Absence of     detectable antibody response. Am. Rev. Respir. Dis. 104: 710-716 -   3. De Repentigny L., Marr L D., Keller J W., Carter A W., Kuydendall     R J., Kaufman L. and Reiss E. 1985. Comparison of enzyme immunoassay     and gas-liquid chromatography for the rapid diagnosis of invasive     candidiasis in cancer patients. J. Clin. Micro 21(6):972-979 -   4. Miyakawa Y., Mabuchi T., Fukazaw Y. 1993. A new method for     detection of Candida albicans in human blood by polymerase chain     reaction. J. Clin. Micro. 31(12): 3344-3347 -   5. Elie C M., Lott T J., Ress E., Morrison C J. 1998. Rapid     detection of Candida species with species specific DNA probes. J.     Clin. Micro. 36 (11): 3260-3265 -   6. Jaeger E., Carrol N., Choudhury S., Dunlop H., et al. 2000. Rapid     detection and identification of Candida, Aspergillus and Fusarium     species in ocular samples using nested PCR. J. Clin. Micro. 38(8):     2902-2908 -   7. Loeffler J., Henke N., Hebart H., Schmidt D., Hagmeyer L.,     Schmacher U. and Einsele H. 2000. Quantification of fungal DNA by     using fluorescence resonance energy transfer and the LightCycler     system. J. Clin. Micro. 38(2):586-90 -   8. White P L., Shetty A., Barnes R A. 2003. Detection of seven     Candida species using the Light-Cycler system. J Med Microbiol.     52(3):229-238 -   9. Pryce T M., Kay I D., Palladino S., Heath C H. 2003. Real-time     automated polymerase chain reaction (PCR) to detect Candida albicans     and Aspergillus fumigatus DNA in whole blood from high-risk     patients. Diagn. Microbiol. Infect. Dis. 47(3):487-496 -   10. Selvarangan R., Bui U., Limaye A P., Cookson B T. 2003. Rapid     identification of commonly encountered Candida species directly from     blood culture bottles. J. Clin. Micro. 41(12):5660-5664 -   11. Staab J F, Ferrer C A., Sundstrom P. 1996. Developmental     expression of a tandemly repeated, proline-and-glutamine-rice amino     acid motif on hyphal surfaces on Candida albicans. J. Biol. Chem.     15; 271(11):6298-305 -   12. Staab J F, Sundstrom P. 1998. Genetic organization and sequence     analysis of the hyphal-specific cell wall protein gene HWP1 of     Candida albicans. Yeast 14(7):681-6 -   13. Sharkey L., McNemar M., Saporito-Irwin S., Sypherd P.,     Fonzi W. 1999. HWP1 functions in the morphological development of     Candida albicans downstream of EFG1, TUP1 and RBF1. J. Bact.     181(17): 5273-5279 -   14. Chang H., Leaw S., Huang A., Wu L, Chang T. 2001. Rapid     identification of yeasts in positive blood cultures by a multiplex     PCR method. J. Clin. Micro 39(10): 3466-3471 

1-34. (canceled) 35: A HWP1 gene sequence or fragment or variants thereof as a target region in a nucleic acid based assay for Candida albicans. 36: A primer derived from a HWP1 gene comprising nucleic acid SEQ ID No. 2 or its reverse compliment or derivative, variants or mutants thereof. 37: A primer derived from a HWP1 gene comprising nucleic acid SEQ ID No. 3 or its reverse compliment or derivative, variants or mutants thereof. 38: A probe derived from a HWP1 gene comprising nucleic acid SEQ ID No. 4 or its reverse compliment or derivative, variants or mutants thereof. 39: A primer derived from a HWP1 gene comprising nucleic acid SEQ ID No. 12 or its reverse compliment or derivative, variants or mutants thereof. 40: A primer derived from a HWP1 gene comprising nucleic acid SEQ ID No. 13 or its reverse compliment or derivative, variants or mutants thereof. 41: A probe derived from a HWP1 gene comprising nucleic acid SEQ ID No. 14 or its reverse compliment or derivative, variants or mutants thereof. 42: A probe derived from a HWP1 gene comprising nucleic acid SEQ ID No. 15 or its reverse compliment or derivative, variants or mutants thereof. 43: A primer/probe combination comprising nucleic SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14 and SEQ ID No. 15 or reverse compliment or derivative, variants or mutants thereof. 44: A nucleic acid comprising a nucleic acid sequence selected from any one or more of SEQ ID No. 1 to 4 and SEQ ID No. 12 to 15 or derivative, variants or mutants thereof. 45: An isolated nucleic acid molecule useful as a probe for identifying C. albicans in a sample selected from any one or more of (i) nucleotide sequence of any of SEQ ID No. 1 to 4 and 12 to 15; (ii) the nucleotide sequence complementary to (i); (iii) a portion of the nucleotide sequence (i) of sufficient length to determine the presence of C. albicans in a sample; and (iv) the nucleotide sequence complementary to (iii) 46: A method for the detection of C. albicans comprising the steps of;— isolating a sample; extracting or releasing DNA from the sample; amplifying a target sequence using an in vitro amplification technology; and determining the presence or absence of C. albicans in the sample using nucleic acid probes, peptide nucleic acid (PNA) probes, other hybrid molecules or antibodies to the target amplified nucleic acid to detect the amplified target. 47: A method for the quantification of HWP1 gene expression in C. albicans comprising the steps of;— isolating a sample; extracting or releasing RNA from the sample; carrying out reverse transcription to produce cDNA; amplifying a target sequence using an in vitro amplification technology; and quantifying the HWP1 gene expression in the sample using nucleic acid probes, peptide nucleic acid (PNA) probes, other hybrid molecules or antibodies to the target amplified nucleic acid to detect the amplified target. 48: A method for the detection of C. albicans comprising the steps of isolating a sample, extracting the nucleic acid and directly detecting the nucleic acid using a specific nucleic acid probe, peptide nucleic acid (PNA) probes, other hybrid molecules or antibodies to the target amplified nucleic acid.
 49. The method as claimed in claim 46 wherein the target sequence is a HWP1 gene sequence or derivative or variants or mutants thereof.
 50. The method as claim in claim 47 wherein the target sequence is a HWP1 gene sequence or derivative or variants or mutants thereof.
 51. The method as claim in claim 48 wherein the target sequence is a HWP1 gene sequence or derivative or variants or mutants thereof.
 52. The method as claimed in claim 46 wherein the target sequence comprises nucleic acid SEQ ID No. 1 or derivative or variants or mutants thereof.
 53. The method as claimed in claim 47 wherein the target sequence comprises nucleic acid SEQ ID No. 1, or derivative or variants or mutants thereof.
 54. The method as claimed in claim 48 wherein the target sequence comprises nucleic acid SEQ ID No. 1, or a derivative or variants or mutants thereof.
 55. The method as claimed in claim 46 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 56. The method as claimed in claim 47 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 48, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 57. The method as claimed in claim 48 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 58. The method as claimed in claim 49 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 59. The method as claimed in claim 50 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 60. The method as claimed in claim 51 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 61. The method as claimed in claim 52 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 62. The method as claimed in claim 53 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 63. The method as claimed in claim 54 wherein the target sequence is detected using a primer or probe selected from any one or more of nucleic acid SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15 or reverse compliments or derivative, mutants or variants thereof.
 64. The method as claimed in claim 55 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 65. The method as claimed in claim 56 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 66. The method as claimed in claim 57 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 67. The method as claimed in claim 58 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 68. The method as claimed in claim 59 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 69. The method as claimed in claim 60 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 70. The method as claimed in claim 61 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 71. The method as claimed in claim 62 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET).
 72. The method as claimed in claim 63 wherein the target sequence is detected using fluorescence resonance energy transfer (FRET). 73: A method for determining the efficacy of an anti-fungal agent, combinations of anti-fungal agents, immuno-modulator drugs, combinations of immuno-modulator drugs, combination of anti-fungal and/or immuno-modulator drugs comprising the steps of;— quantifying the expression of the HWP1 gene, mRNA products of expression, or signals derived from hybridisation to products of expression or derivative or mutants or variants thereof in a clinical sample prior to administration of therapy, administering an anti-fungal agent, combinations of anti-fungal agents, immuno-modulator drugs, combinations of immuno-modulator drugs, or combination of anti-fungal and immuno-modulator drugs; and quantifying the expression of the HWP1 gene mRNA products of expression or signals derived from hybridisation to products of expression in a clinical sample after therapy.
 74. The method as claimed in claim 73 wherein the expression levels of the HWP1 gene in a clinical sample is monitored over a period of time.
 75. The method as claimed in claim 73 wherein the clinical sample is selected from any one or more of blood, sputum, urine, BAL, saliva, stool sample, vaginal and mouth swab, periodontal tissue, or bone, environmental sample, manufacturing process sample, and sterile injectable products for release. 76: A method of screening anti-fungal compounds for the treatment and/or prophylaxis of C. albicans fungal infection, comprising detecting the presence or absence of C. albicans before and after treatment with the anti-fungal compounds using the HWP1 gene or derivative, mutants or variants thereof. 77: A method of screening combinations of anti-fungal compounds for the treatment and/or prophylaxis of C. albicans fungal infection, comprising detecting the presence or absence of C. albicans before and after treatment with the anti-fungal compounds using the HWP1 gene or derivative, mutant or variant thereof. 78: A method of screening immuno-modulator compounds for the treatment and/or prophylaxis of C. albicans fungal infection, comprising detecting the presence or absence of C. albicans before and after treatment with the immunomodulator compounds using the HWP1 gene or derivative, mutant or variant thereof. 79: A method of screening combinations of anti-fungal and immuno-modulator compounds for the treatment and/or prophylaxis of C. albicans fungal infection, comprising detecting the presence or absence of C. albicans before and after treatment with the combination of anti-fungal and immuno-modulator compounds using the HWP1 gene or derivative, mutant or variant thereof. 80: A diagnostic kit comprising a HWP1 gene sequence for detecting the presence of C. albicans in a sample.
 81. The diagnostic kit as claimed in claim 80 wherein the HWP1 gene sequence comprises SEQ ID No. 1 or derivative, mutants or variants thereof. 82: A diagnostic kit comprising a nucleic acid sequence selected from any one or more of SEQ ID No. 2 to 4 or 12 to 15 for detecting the presence of C. albicans in a sample.
 83. The kit as claimed in claim 80 wherein the sample is selected from any one or more of a clinical, veterinary, environmental, industrial, manufacturing process and food sample.
 84. The kit as claimed in claim 82 wherein the sample is selected from any one or more of a clinical, veterinary, environmental, industrial, manufacturing process and food sample.
 85. The kit as claimed in claim 80 wherein the sample is selected from any one or more of blood, sputum, urine, BAL, saliva, stool sample, vaginal and mouth swab periodontal tissue, or bone, environmental sample, manufacturing process sample, sterile injectable products for release.
 86. The kit as claimed in claim 82 wherein the sample is selected from any one or more of blood, sputum, urine, BAL, saliva, stool sample, vaginal, mouth swab periodontal tissue, or bone, environmental sample, manufacturing process sample, sterile injectable products for release. 87: A use of a nucleic acid sequence selected from any one or more of SEQ ID No. 1 to 4 and 12 to 15 or a derivative, mutants or variants thereof in the detection of C. albicans. 88: A use of the HWP1 gene, HWP1 RNA or a derivative, mutants or variants thereof for use in the detection of C. albicans.
 89. The use as claimed in claim 88 wherein the HWP1 gene comprises the forward DNA strand and the nucleotide sequence complementary thereto.
 90. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 36 in the detection of C. albicans.
 91. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 37 in the detection of C. albicans.
 92. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 38 in the detection of C. albicans.
 93. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 39 in the detection of C. albicans.
 94. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 40 in the detection of C. albicans.
 95. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 41 in the detection of C. albicans.
 96. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 42 in the detection of C. albicans.
 97. The use of a probe and/or primer or probe/primer combination or reverse compliment thereof as claimed in claim 43 in the detection of C. albicans. 